Lupin Recalls Quinapril Tablets Due to Unknown Impurity
Lupin Pharmaceuticals is recalling Quinapril tablets because an unknown impurity exceeded specification limits during stability testing.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves an unknown impurity exceeding specifications, which fits the 'High' severity criteria for risk-of-harm products where injury has not yet been reported.
Plain-English summary
Lupin Pharmaceuticals, Inc. is recalling Quinapril Tablets USP, 5 mg, 90 count bottles. The recall affects 30,264 bottles distributed nationwide and in Puerto Rico. The specific lots involved are 3104879, 3104880 (Exp. 10/13), 3110218, 3110219, and 3110220 (Exp. 12/13).
The recall was initiated because an unknown impurity was found to be above the specification limit during stability testing at the 36-month test interval. This is a Class II recall, indicating a situation where use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.
Consumers with these specific lots of Quinapril tablets should stop using them and contact their healthcare provider or pharmacist for guidance on replacement or disposal.
The recalled product
- Product
- QUINAPRIL (QUINAPRIL)
- Brand
- QUINAPRIL
- Manufacturer
- Lupin Pharmaceuticals Inc.
- Category
- Drug — Prescription Drug
- Hazard
- Affected units
- 30,264
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lots 3104879
- 3104880
- Exp. 10/13
- 3110218
- 3110219
- 3110220 Exp. 12/13
UPCs (2)
- 0368180559092
- 0368180556091
Distribution
Part of a larger recall action
This product is one of 2 recalled by Lupin Pharmaceuticals Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · QUINAPRIL
- HighQuinapril Tablets Recalled Due to Excess Impurity Above Limits
FDA (Drugs) · 2022-12-28
- HighPrescription Drug Quinapril Recalled for Chemical Impurity Exceeding Safety Limits
FDA (Drugs) · 2022-12-28
- ModerateLupin Recalls Quinapril Tablets Due to Impurity A Specification Failure
FDA (Drugs) · 2017-04-12
- HighLupin Recalls Quinapril Tablets Due to Unknown Impurity Exceeding Limits
FDA (Drugs) · 2014-01-22
Same manufacturer · Lupin Pharmaceuticals Inc.
See all →- ModerateLupin Recalls Clobetasol Propionate Cream for Content Uniformity Failures
FDA (Drugs) · 2026-09-02
- SevereGlucagon Emergency Kit Recalled for Manufacturing Process Deviation
FDA (Drugs) · 2026-07-08
- HighPrednisolone Acetate Ophthalmic Suspension Recalled for Foreign Substance
FDA (Drugs) · 2026-07-08
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- ModerateGanirelix acetate injection recalled after failing an impurity specification
FDA (Drugs) · 2025-12-17
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17